IP Verse

Deva Holding Anonim Sirketi competitive analysis

Latest oppositions filed by Deva Holding Anonim Sirketi

Explore patent oppositions filed by Deva Holding Anonim Sirketi against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 2, 2026
Patent NumberTitleApplicantOpposition Date
EP3377534
Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 AntibodyBRISTOL MYERS SQUIBBMar 11, 2026
EP4338805
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026
EP4342546
Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin TherapyAMARIN PHARMACEUTICALS IRELANDFeb 26, 2026
EP4218732
Tablets Comprising Eltrombopag OlamineNOVARTISDec 16, 2025
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 22, 2025

Latest PTAB cases involving Deva Holding Anonim Sirketi

Discover the latest PTAB cases involving Deva Holding Anonim Sirketi, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Deva Holding Anonim Sirketi with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 2, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DEVA HOLDING ANONIM SIRKETI5 - - -
AMARIN PHARMACEUTICALS IRELAND - 20 - 1
BRISTOL MYERS SQUIBB - 90 - 8
NOVARTIS6520 - 21